Cargando…
Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547803/ https://www.ncbi.nlm.nih.gov/pubmed/34723209 http://dx.doi.org/10.1016/S2665-9913(21)00328-3 |
| _version_ | 1784590450642911232 |
|---|---|
| author | Schmiedeberg, Kristin Vuilleumier, Nicolas Pagano, Sabrina Albrich, Werner C Ludewig, Burkhard Kempis, Johannes von Rubbert-Roth, Andrea |
| author_facet | Schmiedeberg, Kristin Vuilleumier, Nicolas Pagano, Sabrina Albrich, Werner C Ludewig, Burkhard Kempis, Johannes von Rubbert-Roth, Andrea |
| author_sort | Schmiedeberg, Kristin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8547803 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85478032021-10-27 Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses Schmiedeberg, Kristin Vuilleumier, Nicolas Pagano, Sabrina Albrich, Werner C Ludewig, Burkhard Kempis, Johannes von Rubbert-Roth, Andrea Lancet Rheumatol Comment Elsevier Ltd. 2022-01 2021-10-26 /pmc/articles/PMC8547803/ /pubmed/34723209 http://dx.doi.org/10.1016/S2665-9913(21)00328-3 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comment Schmiedeberg, Kristin Vuilleumier, Nicolas Pagano, Sabrina Albrich, Werner C Ludewig, Burkhard Kempis, Johannes von Rubbert-Roth, Andrea Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title | Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title_full | Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title_fullStr | Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title_full_unstemmed | Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title_short | Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| title_sort | efficacy and tolerability of a third dose of an mrna anti-sars-cov-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses |
| topic | Comment |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547803/ https://www.ncbi.nlm.nih.gov/pubmed/34723209 http://dx.doi.org/10.1016/S2665-9913(21)00328-3 |
| work_keys_str_mv | AT schmiedebergkristin efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT vuilleumiernicolas efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT paganosabrina efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT albrichwernerc efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT ludewigburkhard efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT kempisjohannesvon efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses AT rubbertrothandrea efficacyandtolerabilityofathirddoseofanmrnaantisarscov2vaccineinpatientswithrheumatoidarthritiswithabsentorminimalserologicalresponsetotwopreviousdoses |